University of South Carolina

Scholar Commons
Faculty Publications

Pharmacy, College of

10-1-2014

Musculoskeletal Safety Outcomes of Patients Receiving
Daptomycin With HMG-COA Reductase Inhibitors
Christopher M. Bland
Department of Clinical Pharmacy, Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia, USA
Department of Clinical Pharmacy & Outcomes Sciences, South Carolina College of Pharmacy at the
University of South Carolina

P Brandon Bookstaver
University of South Carolina - Columbia

Z Kevin Lu
University of South Carolina - Columbia, lu32@email.sc.edu

Brianne L. Dunn
University of South Carolina - Columbia, dunn@cop.sc.edu

Kathey Fulton Rumley
Department of Internal Medicine, Vidant Medical Center, Greenville, North Carolina, USA Campbell
University School of Pharmacy

Follow this and additional works at: https://scholarcommons.sc.edu/phar_facpub
Part of the Pharmacy and Pharmaceutical Sciences Commons

Publication Info
Published in Antimicrobial Agents and Chemotherapy, Volume 58, Issue 10, 2014, pages 5726-5731.
Copyright © American Society for Microbiology, Antimicrobial Agents and Chemotherapy. https://doi.org/
10.1128/AAC.02910-14, 2014

This Article is brought to you by the Pharmacy, College of at Scholar Commons. It has been accepted for inclusion
in Faculty Publications by an authorized administrator of Scholar Commons. For more information, please contact
digres@mailbox.sc.edu.

Musculoskeletal Safety Outcomes of Patients Receiving Daptomycin
with HMG-CoA Reductase Inhibitors
Christopher M. Bland,a,b P. Brandon Bookstaver,b Z. Kevin Lu,b Brianne L. Dunn,b
Kathey Fulton Rumleyc,d, the Southeastern Research Group Endeavor (SERGE-45)
Department of Clinical Pharmacy, Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia, USAa; Department of Clinical Pharmacy & Outcomes Sciences,
South Carolina College of Pharmacy at the University of South Carolina, Columbia, South Carolina, USAb; Department of Internal Medicine, Vidant Medical Center,
Greenville, North Carolina, USAc; Campbell University School of Pharmacy, Buies Creek, North Carolina, USAd

D

aptomycin is a cyclic lipopeptide antibiotic that has become
an important agent in the treatment of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant Enterococcus (VRE) species. It
is FDA approved for use in Gram-positive skin and skin structure
infections (SSSI) and S. aureus bacteremia, including right-sided
infective endocarditis at doses of 4 mg/kg of body weight and 6
mg/kg once daily, respectively (1). Myalgias, serum creatine phosphokinase (CPK) elevations, and muscle weakness were noted in
preapproval clinical trials at doses of 4 mg/kg twice daily (2). Decreasing the dosing interval to once daily (the FDA-approved dosing interval) significantly reduced the incidence of drug-induced
musculoskeletal toxicity. In postmarketing studies, higher doses
of daptomycin (⬎6 mg/kg) have been associated with modest increases in toxicity risk (3, 4). CPK monitoring is recommended
once every 7 days during daptomycin therapy (1).
Concomitant use of daptomycin and 3-hydroxy-3-methylglutaryl– coenzyme A (HMG-CoA) reductase inhibitors (statins) is
not uncommon, but it carries concerns for potential synergistic
musculoskeletal toxicities. Risk factors for statin-induced muscle
toxicity include older age, high statin dosage, female gender, and
renal disease (5). Concomitant use of cytochrome P450 inhibitors
such as amiodarone and other myotoxic drugs such as fibric acid
derivatives increases the risk of statin-induced rhabdomyolysis
(6). Daptomycin product labeling recommends that consideration be given to discontinuing statin therapy while administering
daptomycin due to potential for additive toxicity, primarily myopathic toxicities. Limited data exist regarding safety of coadministration of daptomycin with statin therapy (4, 7, 8, 9). The objec-
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tive of our study was to report on the safety of concomitant statin
and daptomycin therapy among hospitalized patients.
(These data were presented in part at the 48th Annual Meeting
of the Infectious Diseases Society of America [IDSA], Vancouver,
BC, Canada, October 2010.)
MATERIALS AND METHODS
This study was a retrospective, multicenter study of adult patients hospitalized from 2005 to 2010 who received daptomycin with or without statin
therapy. The first dose of daptomycin was used to determine inclusion
into the study, with dosing based on actual body weight. The Institutional
Review Board at each participating site approved the study prior to data
collection. Patients ⱖ18 years of age hospitalized from January 2005 to
May 2010 who received daptomycin for a minimum of 7 days with concurrent statin therapy for at least 24 h as part of routine care during
hospitalization were included in the combination group. Patients receiving daptomycin for at least 7 days without statin therapy comprised the
other group. CPK monitoring was left at the discretion of the treating
clinician. CPKs were considered baseline from 1 month prior to the day of
initiation of daptomycin therapy. Utilizing medical records and data documented on standardized case report forms collected during the complete
course of therapy, we obtained detailed information on patient demographics, treatment indication, estimated creatinine clearance (CrCl), sta-
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Daptomycin, a cyclic lipopeptide antibiotic, and 3-hydroxy-3-methylglutaryl– coenzyme A (HMG-CoA) reductase inhibitors
(statins) are commonly administered in the inpatient setting and are associated with creatine phosphokinase (CPK) elevations,
myalgias, and muscle weakness. Safety data for coadministration of daptomycin with statins are limited. To determine the safety
of coadministration of daptomycin with statin therapy, a multicenter, retrospective, observational study was performed at 13
institutions in the Southeastern United States. Forty-nine adult patients receiving statins concurrently with daptomycin were
compared with 171 patients receiving daptomycin without statin therapy. Detailed information, including treatment indication
and duration, infecting pathogen, baseline and subsequent CPK levels, and presence of myalgias or muscle complaints, was collected. Myalgias were noted in 3/49 (6.1%) patients receiving combination therapy compared with 5/171 (2.9%) of patients receiving daptomycin alone (P ⴝ 0.38). CPK elevations of >1,000 U/liter occurred in 5/49 (10.2%) patients receiving combination
therapy compared to 9/171 (5.3%) patients receiving daptomycin alone (P ⴝ 0.32). Two of five patients experiencing CPK elevations of >1,000 U/liter in the combination group had symptoms of myopathy. Three patients (6.1%) discontinued therapy due
to CPK elevations with concurrent myalgias in the combination group versus 6 patients (3.5%) in the daptomycin-alone group
(P ⴝ 0.42). CPK levels and myalgias reversed upon discontinuation of daptomycin therapy. Overall musculoskeletal toxicity was
numerically higher in the combination group but this result was not statistically significant. Further prospective study is warranted in a larger population.

Safety of Daptomycin with HMG-CoA Reductase Inhibitors

RESULTS

The study sample included 220 patients, of whom a total of 49
patients received concomitant daptomycin and statin therapy.
Demographic characteristics of patients who received statins versus those who did not are shown in Table 1. Patients with statin
use were older and received higher absolute doses of daptomycin,
although the mg/kg doses were similar in the two groups. The
primary diagnoses among the groups included bacteremia/endocarditis (n ⫽ 106), SSSI (n ⫽ 33), and bone/joint infections, including osteomyelitis (n ⫽ 32). Thirteen patients with bone/joint
infections, including osteomyelitis, and 7 patients with SSSI had
concurrent bacteremia. Primary pathogens included S. aureus
(53%), Enterococcus species (18%), and coagulase-negative staphylococci (9%). Ninety-two of 117 S. aureus isolates were MRSA
(79%). The mean duration of daptomycin therapy was 21 days
(range, 7 to 74 days).
Patients with and without statin use had similar patterns of
musculoskeletal side effects (Table 2). Serum CPK elevations of
⬎1,000 U/liter occurred in 5 (10.2%) patients receiving statins
versus 9 (5.3%) not receiving statins (P ⫽ 0.32). Table 3 reports
characteristics of patients with statin therapy who experienced an
adverse effect. All patients were 50 years of age or older, although
the mean age of the population was 63 years. The median time to
a CPK elevation of ⬎1,000 U/liter occurred at 11.5 days of daptomycin therapy. Three of the five patients receiving concurrent
statins also reported symptoms of myopathy. One patient who
experienced toxicity had a CrCl of ⬍40 ml/min and was receiving
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approximately 9 mg/kg of daptomycin daily. All patients in the
combination group who experienced a CPK of ⬎1,000 U/liter or
myalgias were on either atorvastatin or simvastatin. One patient
experienced rhabdomyolysis, which resolved upon discontinuation of therapy.
Our unadjusted logistic regression analysis showed that compared to patients using daptomycin alone, those using both daptomycin and statin were associated with 2.05 times the risk of
experiencing musculoskeletal side effects (OR, 2.05); however,
this finding was not statistically significant (95% confidence interval [CI], 0.65 to 6.41). Results were similar after controlling for
potential confounders (Table 4). Statin use was not significantly
associated with potential musculoskeletal side effects (OR, 1.35;
95% CI, 0.35 to 5.18) in the adjusted logistic regression analysis.
African-American race was significantly associated with an increased risk for musculoskeletal side effects (OR, 3.95; 95% CI,
1.12 to 13.91). We further performed a subanalysis using multivariable logistic regression to examine the dose-response effect
and to determine whether patients receiving high doses of statin
(ⱖ40 mg) were more likely to experience CPK elevations or myalgias than patients with low doses of stain (⬍40 mg). We did not
find a statistically significant association (OR, 4.60; 95% CI, 0.47
to 44.60). Similar results were obtained for lower daptomycin dosages (⬃4 mg/kg) (OR, 2.84; 95% CI, 0.84 to 9.60).
DISCUSSION

This multicenter, retrospective, comparator study of patients receiving daptomycin alone versus daptomycin with statin therapy
demonstrated similar rates of musculoskeletal toxicity with low
discontinuation rates in the two groups. In interpreting our findings, several factors should be considered.
Daptomycin product labeling advises caution on the combination of daptomycin and statin therapy, but coprescribing is not a
contraindication. Although controversial, continuation of statin
therapy has been associated with decreased mortality in patients
with bacteremia, possibly due to its anti-inflammatory effects
(11).
Safety data with daptomycin and statin coadministration are
limited. A retrospective review of 94 patients included in the Cubicin Outcomes Registry and Experience (CORE) database who
received doses of ⱖ8 mg/kg of daptomycin demonstrated similar
adverse event rates, with 3.2% of patients experiencing increases
in CPK levels, but only 14 patients were on concomitant statin
therapy (4). A recent multicenter study examined safety and efficacy of high-dose daptomycin in patients with invasive Grampositive infections (3). Of 250 patients studied, 24 (9.6%) received
a median dose of 9.7 mg/kg of daptomycin with concomitant statin therapy. Three of 24 patients (12.5%) experienced CPK values
of ⬎200 U/liter on high-dose daptomycin therapy. While on statin therapy, no patient discontinued daptomycin therapy due to
myopathy or myalgias. A recent two-center study found the combination to be safe compared to daptomycin therapy alone (9).
However, the dose for morbidly obese patients was based on ideal
body weight (IBW) according to the average weight of their population, which was approximately 30 kg below that of our population (75 kg versus 106 kg). None of these studies reported the
safety of daptomycin based on an absolute dose. A recent singlecenter study revealed a 2-fold increased risk of CPK elevation,
which was similar to our multicenter data but was not statistically
significant (7). The mean daptomycin dosage and BMI were 5.3
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tin therapy, serum CPK concentrations, presence of myalgias or muscle
complaints, and reason for daptomycin discontinuation (if applicable).
Estimated renal clearance was calculated with the Cockcroft-Gault formula using actual body weight as recommended by the manufacturer (1).
Primary safety outcomes were compared between the two groups (the
combination daptomycin and statin group and the daptomycin-alone
group) as follows: (i) incidence of serum CPK levels of ⬎1,000 U/liter at
any point during therapy; (ii) documented myalgias or related muscle
pains during therapy; and (iii) number of patients requiring discontinuation of therapy or dose modification due to increased serum CPK levels
with or without signs/symptoms of myopathy.
Data were abstracted into a central spreadsheet database for analysis.
Logistic regression models predicted the probability of significant adverse
event occurrence, defined as CPK levels of ⬎1,000 U/liter or myalgias.
Categorical variables were compared with the chi-squared or Fisher’s exact test, as appropriate. Two independent-sample t tests were used to
compare continuous variables. For model-building purposes, variables in
the logistic regression model were based on evidence from our exploratory analysis, literature, and our research questions. All variables used
were categorical for rational interpretation of beta-coefficients and odds
ratios (ORs). Continuous variables were converted into appropriate categories. Differences were considered statistically significant at P values of
ⱕ0.05. Categorical predictors included age (⬍65 years versus ⱖ65 years),
gender (male versus female), race (African American [AA] versus not
AA), body mass index (BMI) (⬍30 kg/m2 versus ⱖ30 kg/m2), statin use
(yes versus no), per kilogram daptomycin dosage (high dose or ⬎6 mg/kg
versus low dose or ⱕ6 mg/kg), and renal function (CrCl ⬍40 ml/min
versus ⱖ40 ml/min). To study the effect of statin use we conducted a
separate analysis for patients treated with and those treated without statins. Additionally, data were analyzed using automated hierarchically
optimal classification tree analysis, an exact (assumption-free) nonlinear
statistical model which explicitly maximizes classification accuracy for the
data sample (10). All analyses were performed using Microsoft Excel 2007
and SAS (SAS Institute Inc., Cary, NC, USA) at the 5% level of significance.

Bland et al.

TABLE 1 Demographics and clinical characteristics
Characteristics

Daptomycin and statin
(n ⫽ 49)

Daptomycin only
(n ⫽ 171)

P

Age (mean ⫾ SD) (yr)

63.02 ⫾ 13.14

56.50 ⫾ 16.70

0.0125

Gender (no. [%])
Female
Male

19 (38.78)
30 (61.22)

61 (35.67)
110 (64.33)

Race (no. [%])
Caucasian
African American
Not identified

37 (75.51)
11 (22.44)
1 (2.04)

113 (66.08)
49 (28.65)
9 (5.26)

Body mass index (no. [%])
18.5–24.9 kg/m2
25.0–29.9 kg/m2
30–34.99 kg/m2
35–39.99 kg/m2
ⱖ40 kg/m2

5 (10.20)
9 (18.37)
10 (20.41)
12 (24.49)
13 (26.53)

45 (26.32)
35 (20.47)
29 (16.96)
26 (15.20)
36 (21.05)

Creatinine clearance (mean ⫾ SD) (ml/min)
Weight (mean ⫾ SD) (kg)
Daptomycin absolute dose (mean ⫾ SD) (mg)
Daptomycin dose (mean ⫾ SD) (mg/kg)

70.47 ⫾ 47.21
105.80 ⫾ 25.82
706.20 ⫾ 198.20
6.78 ⫾ 1.33

86.52 ⫾ 57.81
99.01 ⫾ 33.96
641.50 ⫾ 189.40
6.75 ⫾ 1.54

Statin type and dose (no. [%])
Atorvastatin
10 mg
20 mg
40 mg
80 mg
Simvastatin
10 mg
20 mg
40 mg
80 mg
Pravastatin
10 mg
20 mg
40 mg
80 mg
Rosuvastatin
5 mg
10 mg
20 mg
Lovastatin
20 mg
Unknown

14 (28.57)
3
4
4
3
22 (44.90)
1
10
9
2
7 (14.29)
2
1
2
2
3 (6.12)
1
1
1
2 (4.08)
2
1 (2.04)

0.6906

0.3859

0.1305
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study, similar to the rates reported in the limited published data
available.
High-dose daptomycin therapy has been traditionally based on
a milligram-per-kilogram basis, defined as ⬎6 mg/kg or even 8 to
10 mg/kg of actual body weight (13). Nearly half (24/49) of our
study population received 6 mg/kg or less, while nearly 70% were
considered obese (BMI, ⬎30 kg/m2). The pharmacokinetic and
pharmacodynamic profiles of daptomycin demonstrate linearity
up to 12 mg/kg in a normal-weight patient; however, there is divergence in obese patients. Exposure to daptomycin (maximum
concentration and area under the curve) following a 4-mg/kg dose
is increased by approximately 25 to 30%, respectively, in moderately and morbidly obese healthy patients compared to matched,
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mg/kg and 30 kg/m2, respectively, which were less than our study
population.
Coadministration of daptomycin with statin therapy in our
study was associated with rates of CPK elevation of ⬎1,000 U/liter
(10%), which were similar to those of previously reported studies
of high-dose daptomycin (3, 4, 12). Three of six patients in our
study who experienced myalgias or CPK levels of ⬎1,000 U/liter
had baseline CPK levels of ⬎200 U/liter. The daptomycin product
labeling does not specify a baseline CPK that should be obtained;
however, clinical interpretation without this baseline value may be
limited, especially in deconditioned patients or those receiving
concomitant myotoxic agents. Concomitant statin therapy was
well tolerated, with a low overall discontinuation rate of 6% in our

0.0918
0.1947
0.0381
0.9118
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TABLE 4 Logistic regression of predictors of significant adverse events

Side effect(s)

Daptomycin and Daptomycin only
statin (n ⫽ 49)
(n ⫽ 171)
(no. [%])
(no. [%])
P

CPK ⬎ 1,000 U/liter
Yes
No

5 (10.20)
44 (89.80)

0.3152

Presence of myalgias/muscle
pains
Yes
3 (6.12)
No
46 (93.88)
Patients requiring
discontinuation of
therapy due to
musculoskeletal
toxicity
Yes
No

9 (5.26)
162 (94.74)
0.3809
5 (2.92)
166 (97.08)
0.4205

3 (6.12)
46 (93.88)

6 (3.51)
165 (96.49)

nonobese controls (14). A subsequent study revealed an approximate 60% increase in maximum concentration and area under the
curve following a 4-mg/kg dose in morbidly obese healthy patients
compared to normal-weight patients (15). A recent study showed
an increased rate of CPK elevation in obese patients, but discontinuation rates remained low (16). Use of actual body weight in all
patients is currently recommended for daptomycin. This implies
some assumption that the safety profile of the drug in obese patients with invasive disease is also maintained.
One of five patients experiencing CPK elevations or myalgias in

Variable

OR

95% CI

Statin user
Age ⱖ 65 yr
Male
African American
BMI ⱖ 30 kg/m2
High dose (⬎6 mg/kg) of daptomycin
Creatinine clearance ⬍ 40 ml/min

1.35
1.48
1.17
3.95
3.80
3.53
0.85

0.35–5.18
0.44–5.01
0.34–4.05
1.12–13.91
0.89–16.28
0.98–12.71
0.25–2.90

our study had a creatinine clearance of ⬍40 ml/min. In our analysis, one patient (patient 4 from Table 3) with CPK levels of
⬎1,000 U/liter on combination therapy would have received every-other-day dosing if the CrCl rate was based on their IBW but
received daily dosing. The use of actual body weight with the
Cockcroft-Gault formula has been demonstrated to overestimate
glomerular filtration rate (GFR) in obese patients receiving daptomycin (15). Overestimation of GFR may lead to more frequent
dosing of daptomycin than appropriate, increasing drug exposure
and subsequent risk of toxicity. The package insert currently recommends using actual body weight in calculations of creatinine
clearance for daptomycin dosing (1). Further studies are needed
to delineate the best formulas to calculate renal function estimation in obese patients requiring daptomycin therapy.
Most patients (45%) in our study received simvastatin as their
concomitant statin. Four of five patients with musculoskeletal
toxicity in the daptomycin-plus-statin group received 40 mg or
more of atorvastatin or simvastatin. Published data have implicated primarily higher doses of simvastatin (40 mg or 80 mg).
Limited case reports demonstrating rhabdomyolysis with coad-

TABLE 3 Clinical characteristics of subjects with CPK elevation of ⬎1,000 U/liter or myalgias

Subject Age
no.
(yr) Gendera Raceb

Body
mass Daptomycin
index indication

Peak CPKd
Daptomycin after
Day of
CrClc
dose, mg
baseline
Statin and dose Daptomycin
occurrence (ml/min) (mg/kg)
(U/liter)
Myalgias (mg)
discontinued

1
2
3

53
58
74

M
M
M

AA
C
C

35
32
36

7
9
4

131
36
136

650 (5.7)
750 (8.9)
1,000 (8.4)

768
4,885
1,582

Yes
Yes
No

Simvastatin 80 Yes
Simvastatin 40 Yese
Atorvastatin 80 No

4
5
6

60
71
70

F
M
M

C
C
AA

51
43
42

14
14
13

94
115
57

750 (5.8)
575 (4.0)
800 (5.9)

15,354
1,936
1,623

Yes
No
No

Atorvastatin 40 Yes
Atorvastatin 20 No
None
Yes

7

51

F

C

39

20

56

800 (7.8)

2,718

No

None

Yes

8

66

F

C

40

19

123

750 (6.6)

2,457

No

None

Yes

9
10
11
12
13
14

80
23
61
46
87
38

M
F
F
M
M
F

C
AA
AA
AA
AA
AA

22
19
39
30
28
39

5
17
2
4
14
11

32
65
15
14
13
150

553 (7.5)
350 (6.8)
735 (7.9)
840 (8.1)
580 (6.1)
650 (5.8)

31
1,864
27
132
37
4,037

Yes
Yes
Yes
Yes
Yes
No

None
None
None
None
None
None

No
Yes
No
No
No
Yes

Osteomyelitis
Osteomyelitis
Skin/skin structure
infection with
bacteremia
Osteomyelitis
Abdominal abscess
Joint infection/
osteomyelitis
Joint infection/
osteomyelitis
Osteomyelitis with
bacteremia
Bacteremia
Bacteremia
Bacteremia
Bacteremia
Bacteremia
Bacteremia

a

M, male; F, female.
AA, African American; C, Caucasian.
c
CrCl, creatinine clearance.
d
CPK, creatine phosphokinase.
e
Patient developed rhabdomyolysis which resolved upon discontinuation of daptomycin therapy.
b
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TABLE 2 Summary of safety endpoints
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ministration of daptomycin and statins have involved primarily
simvastatin (17, 18). Higher doses of simvastatin (specifically the
80-mg dose) have been associated with increased rates of musculoskeletal adverse events and rhabdomyolysis compared to lower
doses (19, 20). Recently, the FDA changed the product labeling for
simvastatin to reflect these higher risks of myopathy. One of our
patients who discontinued therapy was receiving 80 mg simvastatin daily. Documented literature reports of patients requiring discontinuation of daptomycin with concurrent statin therapy due to
severe myalgias or rhabdomyolysis have mostly involved simvastatin (18, 21).
Some limitations of our study should be acknowledged. First,
the study was nonblinded and retrospective in nature, and thus it
was difficult to establish a causal relationship. Second, the study
endpoints are generally rare events, so the study may be potentially subject to type II error, which requires a larger sample size.
Third, the logistic regression model may be subject to overparameterization due to rare events, which may lead to larger confidence
intervals. Based on the data, we did not find daptomycin combination therapy with statins to be statistically associated with the
reported adverse events. Baseline and subsequent CPK values
were available for most but not all patients. Receipt of drugs
known to pose additional risk for myopathies and rhabdomyolysis
when added to statin therapy (e.g., fibrates and inhibitors of cytochrome P450 3A4 [CYP3A4]) was not assessed.
In summary, higher rates of CPK elevation of ⬎1,000 U/liter or
myalgias were seen in patients receiving daptomycin with concomitant statin therapy, but this value was not statistically significant compared to rates observed in patients receiving no statin
therapy. Concomitant administration of both agents was well tolerated, with a low discontinuation rate. Statin therapy should not
impede practitioners from prescribing daptomycin concurrently
when clinically indicated to hospitalized patients who develop serious infections. Future study in larger populations is warranted.
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